Melanotan 2 (MT2) · Research brief

Melatonin Science Explained — Mechanisms & Biology

Real Peptides Research TeamEditorial

Updated March 31, 202610 min read

60 WORDS

Short answer

Key takeaways

Melatonin is synthesized in the pineal gland from tryptophan through a four-step pathway, with the rate-limiting enzyme AANAT increasing 100-fold at night in response to darkness signals detected by melanopsin-containing retinal ganglion cells.
MT1 receptors in the suprachiasmatic nucleus reduce neuronal firing to lower wake drive, while MT2 receptors mediate circadian phase shifts. Early evening administration advances your rhythm, late night or early morning delays it.
Blue light at 480nm wavelength suppresses melatonin by 50% or more even at illuminances as low as 200 lux, explaining why screen exposure within two hours of bedtime delays sleep onset by 60–90 minutes on average.
Oral melatonin has bioavailability of 10–56% due to first-pass metabolism and a half-life of 20–50 minutes, making precise timing far more important than dose. Taking it at the wrong circadian phase can shift your rhythm in the unintended direction.
Clinical evidence supports melatonin for jet lag and delayed sleep phase disorder but shows minimal benefit for primary insomnia in adults with normal circadian timing, where cognitive behavioral therapy for insomnia (CBT-I) outperforms supplementation by every metric.

Most people think melatonin just makes you sleepy. That's not quite right. Melatonin is a chronobiotic. A molecule that tells every cell in your body what time it is. Without it, your liver wouldn't know when to process glucose, your immune system wouldn't know when to ramp up surveillance, and your core body temperature wouldn't drop at the right time to permit sleep. The hormone itself doesn't induce unconsciousness the way a sedative does. It orchestrates the biological conditions that make sleep possible.

We've worked with researchers studying circadian biology for years, and the gap between public understanding and actual mechanism is wider here than almost anywhere else in wellness. Melatonin science explained properly requires understanding receptor pharmacology, synthesis pathways, and why your smartphone is more disruptive to sleep than most people realize.

What is melatonin and how does it regulate sleep?

Melatonin is an indoleamine hormone synthesized by the pineal gland in response to darkness, acting on MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) to synchronize circadian rhythms across peripheral tissues. Peak plasma concentration occurs between 2–4 AM in most adults, with levels suppressed to near-zero during daylight hours by retinal ganglion cells that detect blue light wavelengths around 480nm. This photosensitive system explains why even brief exposure to screens or overhead lighting after sunset can delay melatonin onset by 60–90 minutes.

Melatonin science explained starts with correcting a common misconception: melatonin doesn't 'cause' sleep the way benzodiazepines or Z-drugs do by potentiating GABA receptors. Instead, it lowers core body temperature by 0.3–0.5°C, reduces alertness signals from the SCN, and opens the 'gate' for sleep to occur naturally. People who take exogenous melatonin and report 'feeling nothing' often misunderstand the mechanism. You won't feel sedated, but your circadian phase will shift if timed correctly. This article covers the exact biosynthetic pathway from tryptophan to N-acetyl-5-methoxytryptamine, how MT1 and MT2 receptor subtypes produce different effects, and what the clinical evidence actually shows about supplementation timing, dose-response curves, and the specific conditions where exogenous melatonin outperforms placebo.

The Biosynthesis Pathway: From Tryptophan to Melatonin

Melatonin synthesis occurs through a four-step enzymatic conversion beginning with the amino acid tryptophan. The pineal gland converts tryptophan to 5-hydroxytryptophan (5-HTP) via tryptophan hydroxylase, then to serotonin via aromatic L-amino acid decarboxylase. The rate-limiting step occurs next: serotonin N-acetyltransferase (AANAT). An enzyme whose activity increases 100-fold at night. Converts serotonin to N-acetylserotonin. Finally, hydroxyindole-O-methyltransferase (HIOMT) adds a methyl group to produce N-acetyl-5-methoxytryptamine, the chemical name for melatonin.

AANAT expression is controlled by norepinephrine released from the superior cervical ganglion in response to darkness signals detected by intrinsically photosensitive retinal ganglion cells (ipRGCs). These specialized cells contain melanopsin, a photopigment maximally sensitive to blue light at 480nm. Explaining why blue-blocking glasses and screen filters specifically targeting this wavelength can preserve nighttime melatonin levels. A 2021 study published in the Journal of Clinical Endocrinology & Metabolism found that two hours of evening iPad exposure (unfiltered) suppressed melatonin by 55% compared to dim red light exposure, with onset delayed by an average of 88 minutes.

The pineal gland releases melatonin directly into the bloodstream and cerebrospinal fluid, with plasma half-life ranging from 20–50 minutes depending on hepatic clearance via CYP1A2 enzymes. This short half-life means exogenous melatonin must be timed precisely. Taking it at the wrong circadian phase can shift your rhythm in the opposite direction intended. The bioavailability of oral melatonin ranges from 10–56% due to extensive first-pass metabolism, which is why 'melatonin didn't work for me' reports often reflect incorrect timing rather than pharmacological failure.

Receptor Pharmacology: MT1, MT2, and Circadian Phase Shifting

Melatonin exerts its effects by binding to two G-protein coupled receptors: MT1 (MEL1A) and MT2 (MEL1B). MT1 receptors are concentrated in the suprachiasmatic nucleus (SCN), the brain's master circadian pacemaker located in the anterior hypothalamus. MT1 activation inhibits neuronal firing in the SCN, reducing the alerting signal that opposes sleep pressure during the biological day. This is the mechanism behind melatonin's acute sleep-promoting effect. Not sedation, but rather removal of wake-promoting drive.

MT2 receptors, also located in the SCN but distributed differently, mediate phase-shifting of the circadian rhythm itself. Administration of melatonin during the late biological day (roughly 2–6 hours before your natural dim light melatonin onset, or DLMO) causes a phase advance. Your rhythm shifts earlier. Administration in the late biological night or early morning causes a phase delay. Your rhythm shifts later. This phase-response curve is why travelers use melatonin to combat jet lag: taking 0.5–3mg at the destination's bedtime for three nights consecutively can accelerate re-entrainment by 50% compared to light exposure alone.

Research from Stanford University's Department of Psychiatry demonstrated that MT2-selective agonists produce phase shifts without the acute sleep-promoting effects of MT1 activation. Establishing that these two receptor subtypes serve distinct functions. Ramelteon (Rozerem), an FDA-approved insomnia medication, is an MT1/MT2 agonist with 3–16 times higher affinity than melatonin itself, allowing effective phase-shifting at 8mg doses. Tasimelteon (Hetlioz), approved for non-24-hour sleep-wake disorder, shows even higher MT2 selectivity.

Melatonin also binds weakly to MT3 receptors (now identified as quinone reductase 2), though the functional significance remains unclear. Some evidence suggests MT3 activation contributes to melatonin's antioxidant effects. Melatonin scavenges hydroxyl radicals and peroxynitrite at concentrations achieved physiologically in cerebrospinal fluid. But this mechanism is secondary to its chronobiotic function. Our experience working with peptide researchers examining circadian biology suggests the receptor-mediated effects are what matter clinically; the antioxidant properties, while real, don't explain why people take melatonin for sleep.

Light, Circadian Disruption, and Melatonin Suppression

Intrinsically photosensitive retinal ganglion cells (ipRGCs) project directly to the SCN via the retinohypothalamic tract, bypassing the visual cortex entirely. This is why even individuals with complete cortical blindness can still entrain circadian rhythms to light-dark cycles. And why closing your eyes at night isn't sufficient if ambient light penetrates the eyelid. ipRGCs respond to light intensity and wavelength, with maximal suppression of melatonin occurring at illuminances above 200 lux and wavelengths centered around 480nm.

A landmark study published in the Journal of Physiology found that 60 minutes of exposure to 200 lux white light (typical indoor overhead lighting) suppressed melatonin by 50%, while the same duration of 10 lux red light (>600nm) produced no measurable suppression. This wavelength sensitivity has led to the widespread recommendation for blue-blocking glasses and red-shifted lighting after sunset. Recommendations supported by controlled trials showing 30–45 minute advances in DLMO with consistent use.

Melatonin science explained must address the modern lighting environment: artificial light at night (ALAN) is ubiquitous, and even low levels matter. A 2022 meta-analysis of 17 studies in Sleep Medicine Reviews found dose-dependent melatonin suppression beginning at 10 lux. Roughly the brightness of a dimmed smartphone screen held at arm's length. The practical implication: dimming alone isn't enough. You need either wavelength filtering (blue blockers) or complete elimination of light sources above 5 lux in the two hours before intended sleep.

Shift workers represent the most severe form of circadian disruption, with chronic suppression of nighttime melatonin linked to increased risk of metabolic syndrome, cardiovascular disease, and certain cancers. The International Agency for Research on Cancer classifies shift work involving circadian disruption as a Group 2A carcinogen (probably carcinogenic to humans), with epidemiological evidence strongest for breast cancer in female nurses. The mechanism appears to involve melatonin's role in regulating cell proliferation and estrogen receptor signaling, though causality remains difficult to establish in observational studies.

Melatonin Science Explained: Clinical Evidence Comparison

Melatonin supplementation shows highly variable efficacy depending on the population studied and the outcome measured. Here's how the evidence breaks down across common use cases:

Indication	Effective Dose	Evidence Quality	Effect Size	Bottom Line
Jet lag (eastward travel)	0.5–5mg at destination bedtime	High (meta-analysis of 10+ RCTs)	Phase advance of 60–90 minutes	Effective. Timing matters more than dose
Delayed sleep phase disorder	0.5–3mg, 2–3 hours before desired bedtime	Moderate (multiple small RCTs)	Sleep onset 30–60 min earlier	Effective when combined with fixed wake time
Primary insomnia (adults)	2–5mg, 30–60 min before bed	Low (inconsistent results)	Sleep latency reduced by 7–12 minutes	Weak effect. Inferior to CBT-I
Insomnia in elderly	2mg prolonged-release	Moderate (Phase III trial data)	Sleep latency reduced by 20 min	Effective. Elderly produce less endogenous melatonin
Shift work sleep disorder	3–5mg before daytime sleep	Low (small trials, high heterogeneity)	No consistent benefit	Ineffective. Mistimed relative to circadian phase
Children with ADHD + insomnia	3–6mg, 30–60 min before bed	Moderate (multiple pediatric RCTs)	Sleep onset 45–60 min earlier	Effective short-term. Long-term safety unclear

The critical distinction in melatonin science explained: exogenous melatonin works best when endogenous production is impaired (elderly, blind individuals) or mistimed relative to desired sleep schedule (jet lag, DSWPD). In primary insomnia with normal circadian phase, the benefit is minimal. A 2019 Cochrane review of 12 trials found sleep latency reductions of 7.2 minutes on average, barely exceeding placebo response. This explains why melatonin 'works' for some people and 'does nothing' for others. The underlying mechanism matters.

What If: Melatonin Science Scenarios

What If I Take Melatonin Too Early or Too Late?

Take it 5–6 hours before your natural DLMO (dim light melatonin onset) and you'll delay your rhythm. The opposite of what most people intend. The phase-response curve shows that melatonin administration during the late biological day (roughly 2–6 hours before DLMO) causes phase advances, while administration in the late biological night or early morning causes phase delays. For most people with a bedtime around 11 PM, DLMO occurs between 9–10 PM, meaning optimal timing for an advance is 5–7 PM. Taking melatonin at midnight when you can't sleep is mistimed. You're past the advance window and into the dead zone where melatonin produces minimal phase shift in either direction.

What If I Use High-Dose Melatonin (10mg or More)?

Doses above 5mg don't produce proportionally larger phase shifts or stronger sleep-promoting effects due to receptor saturation. MT1 and MT2 receptors are fully occupied at plasma concentrations achieved with 0.5–3mg oral doses. Higher doses extend the duration of receptor occupancy (due to slower clearance) but don't increase peak effect. Some evidence suggests supraphysiological doses (10–100mg) may produce antioxidant effects via receptor-independent mechanisms, but these doses are unnecessary for circadian or sleep applications. A 2021 study in the Journal of Pineal Research found no difference in sleep latency between 3mg and 10mg melatonin in healthy adults, and next-day grogginess was significantly more common in the 10mg group.

What If I'm a CYP1A2 Rapid Metabolizer?

CYP1A2 is the primary enzyme responsible for hepatic clearance of melatonin, and genetic polymorphisms produce 10-fold variability in metabolic rate between individuals. Rapid metabolizers (*1F/*1F genotype) clear melatonin within 15–20 minutes, meaning standard 2–3mg doses produce a brief spike followed by rapid decline. Potentially explaining 'non-responder' reports. These individuals may benefit from sustained-release formulations (e.g., Circadin 2mg) that maintain plasma levels for 8–10 hours, or from split dosing: 1mg immediate-release at 6 PM plus 1mg at 9 PM rather than 3mg at once.

The Mechanistic Truth About Melatonin

Here's the honest answer: melatonin is a chronobiotic, not a hypnotic. If your circadian rhythm is already aligned with your desired sleep schedule and you don't have impaired endogenous production, exogenous melatonin will do very little. The data for primary insomnia in adults is weak. Sleep latency reductions average 7–12 minutes, which is clinically insignificant and barely distinguishable from placebo in individual cases.

Melatonin works when there's a timing problem: jet lag, shift work (if timed correctly, which is difficult), delayed sleep phase disorder, or age-related decline in pineal function. It doesn't work by 'knocking you out'. It works by resetting your internal clock and opening the biological gate for sleep. If you take it expecting sedation, you'll be disappointed. If you take it to shift your phase and pair it with consistent light exposure and wake time, it's one of the most effective chronobiotic interventions available.

The supplement industry has obscured this by marketing melatonin as a sleep aid comparable to sedative-hypnotics. It isn't. The mechanism is completely different, the dosing requirements are far more precise, and the population that benefits is narrower than the marketing suggests. Melatonin science explained properly means understanding that this is a timing signal. And if your timing is already correct, adding more signal doesn't help.

Biological research continues to explore melatonin's role in immune function, metabolic regulation, and neuroprotection. Melatonin receptors are expressed in peripheral tissues including pancreatic beta cells, adipocytes, and immune cells, suggesting broader physiological roles beyond circadian regulation. Some evidence links chronic circadian disruption and melatonin suppression to increased risk of type 2 diabetes and metabolic syndrome, though causality remains difficult to establish. At Real Peptides, we focus on research-grade compounds that support investigations into these complex biological pathways. Precision tools for understanding the mechanisms that govern human physiology. For researchers studying circadian biology, peptide signaling, or neuroendocrine pathways, our commitment to purity and exact sequencing ensures your studies aren't compromised by compound variability. You can explore our full range of research peptides or learn more about compounds like Pinealon, which researchers use to examine peptide regulation of pineal function.

The future of melatonin science lies not in higher doses or novel formulations, but in precision chronotherapy. Individualized timing based on genetic metabolic profiles, measured DLMO, and real-time circadian phase assessment. Wearable devices that track core body temperature, heart rate variability, and activity patterns are beginning to estimate circadian phase with sufficient accuracy to guide melatonin timing recommendations. That's where the field is headed: personalized, mechanism-driven interventions that respect the biology rather than trying to override it with brute-force dosing.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Melatonin binds to MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) of the hypothalamus — MT1 activation reduces wake-promoting neuronal firing, while MT2 activation shifts circadian phase depending on timing of administration. It lowers core body temperature by 0.3–0.5°C and removes the alerting signal that opposes sleep pressure, but it does not act as a sedative like GABA-modulating drugs. The effect is chronobiotic (time-of-day signaling) rather than hypnotic (direct sleep induction).

For phase advance (shifting sleep earlier), take 0.5–3mg approximately 2–3 hours before your desired bedtime, which corresponds to 5–6 hours before your natural dim light melatonin onset (DLMO). Higher doses (5–10mg) do not produce stronger effects due to receptor saturation — bioavailability is 10–56% and half-life is 20–50 minutes, so timing matters far more than dose. Taking melatonin at the wrong circadian phase (late night or early morning) can delay your rhythm rather than advance it.

Melatonin is effective for jet lag, particularly eastward travel — taking 0.5–5mg at the destination’s bedtime for three consecutive nights accelerates re-entrainment by 50% compared to light exposure alone. For shift work sleep disorder, results are inconsistent because timing is difficult: taking melatonin before daytime sleep after a night shift is often mistimed relative to the worker’s actual circadian phase. The best results occur when melatonin is paired with properly timed bright light exposure and a fixed sleep schedule.

Intrinsically photosensitive retinal ganglion cells (ipRGCs) contain melanopsin, a photopigment maximally sensitive to blue light at 480nm wavelength. These cells project directly to the suprachiasmatic nucleus and suppress melatonin synthesis by inhibiting norepinephrine release to the pineal gland. Even 60 minutes of 200 lux blue-enriched white light (typical smartphone or tablet screen) can suppress melatonin by 50% and delay sleep onset by 60–90 minutes, while red light above 600nm produces negligible suppression at the same intensity.

Short-term use (up to 12 weeks) appears safe in pediatric populations, particularly for children with ADHD or autism spectrum disorder who have delayed sleep onset — clinical trials show sleep onset advancing by 45–60 minutes with 3–6mg doses. However, long-term safety data beyond one year is lacking, and there are theoretical concerns about exogenous melatonin suppressing endogenous production or affecting pubertal development since melatonin modulates reproductive hormones. Pediatric use should be supervised by a physician and paired with behavioral sleep interventions.

No — the evidence is weak. A 2019 Cochrane review of 12 randomized controlled trials found that melatonin reduced sleep latency by an average of just 7.2 minutes compared to placebo in adults with primary insomnia and normal circadian phase. This effect size is clinically insignificant and far smaller than cognitive behavioral therapy for insomnia (CBT-I), which produces 30–45 minute reductions in sleep latency. Melatonin works when there is a circadian timing problem, not when the issue is sleep initiation despite correct timing.

Nocturnal melatonin levels decline progressively after age 40, with peak concentrations in elderly adults often 50–70% lower than in young adults — likely due to calcification of the pineal gland and reduced norepinephrine signaling. This explains why exogenous melatonin shows stronger effects in elderly populations: a Phase III trial of 2mg prolonged-release melatonin in adults over 55 found sleep latency reductions of 20 minutes, significantly larger than effects seen in younger adults with intact endogenous production.

DLMO is the time at which melatonin levels rise above a threshold (typically 3–10 pg/mL in saliva) under dim light conditions, occurring approximately 2–3 hours before habitual sleep time in most adults. It is the gold-standard marker of circadian phase because it reflects SCN output independent of sleep-wake behavior. DLMO matters for melatonin supplementation timing: to advance your rhythm (shift earlier), you must take melatonin 2–6 hours before your DLMO — which is not the same as ‘before bed’ if your sleep schedule is already delayed.

No evidence of physical dependence or tolerance has been documented in clinical trials, even with continuous use for 6–12 months. Melatonin does not suppress endogenous production the way exogenous testosterone suppresses natural hormone synthesis — receptor downregulation does not occur at physiological doses. However, psychological dependence can develop if users believe they ‘cannot sleep’ without it, and inconsistent timing or inappropriate dosing can mask underlying circadian rhythm disorders that require different treatment.

Next-day grogginess typically occurs when high doses (10mg or more) are taken, plasma levels remain elevated into the morning due to individual differences in CYP1A2 metabolism, or when immediate-release formulations are taken too late (within 4–5 hours of desired wake time). Headaches are reported in 5–10% of users in clinical trials and may reflect vasodilatory effects or rebound once melatonin clears. Slow metabolizers or those taking CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) are at higher risk for prolonged effects and should use lower doses.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA